Abbott Laboratories (ABT) : West Oak Capital reduced its stake in Abbott Laboratories by 1.19% during the most recent quarter end. The investment management company now holds a total of 38,240 shares of Abbott Laboratories which is valued at $1.6 Million after selling 460 shares in Abbott Laboratories according to a report filed by the company on Apr 5, 2016 with the SEC.Abbott Laboratories makes up approximately 1.26% of West Oak Capital’s portfolio.
Other Hedge Funds, Including , Nadler Financial Group boosted its stake in ABT in the latest quarter, The investment management firm added 1,304 additional shares and now holds a total of 12,388 shares of Abbott Laboratories which is valued at $526,242. Abbott Laboratories makes up approx 0.23% of Nadler Financial Group’s portfolio.Lvm Capital Management Ltdmi reduced its stake in ABT by selling 4,600 shares or 10.22% in the most recent quarter. The Hedge Fund company now holds 40,395 shares of ABT which is valued at $1.7 Million. Abbott Laboratories makes up approx 0.55% of Lvm Capital Management Ltdmi’s portfolio.Beacon Financial Group boosted its stake in ABT in the latest quarter, The investment management firm added 3,506 additional shares and now holds a total of 14,112 shares of Abbott Laboratories which is valued at $595,385. Abbott Laboratories makes up approx 0.13% of Beacon Financial Group’s portfolio.Renaissance Investment Group reduced its stake in ABT by selling 218 shares or 2.85% in the most recent quarter. The Hedge Fund company now holds 7,430 shares of ABT which is valued at $313,472. Abbott Laboratories makes up approx 0.16% of Renaissance Investment Group’s portfolio.
On the company’s financial health, Abbott Laboratories reported $0.62 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $0.61. The company had revenue of $5188.00 million for the quarter, compared to analysts expectations of $5254.57 million. The company’s revenue was down -3.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.71 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 45 from a previous price target of $51 .
Abbott Laboratories opened for trading at $42.47 and hit $42.88 on the upside on Monday, eventually ending the session at $42.48, with a gain of 0.26% or 0.11 points. The heightened volatility saw the trading volume jump to 39,48,803 shares. Company has a market cap of $62,583 M.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.